Long-term observations of clinicopathological characteristics and outcome of Japanese patients with pauci-immune crescentic

Background The clinicopathological characteristics and outcome with pauci-immune crescentic glomerulonephritis (CreGN) are presumed to vary over time. We examined the characteristics and outcome of Japanese patients with CreGN according to the treatment periods. Patients and methods From 1968 to 2011, we examined a total of 102 patients diagnosed with pauci-immune CreGN by renal biopsy. The patients were divided into three groups according to the treatment periods—Group I (1968–1988, n = 18), Group II (1989–2001, n = 37; when the nationwide survey of rapidly progressive glomerulonephritis [RPGN] was performed in Japan), and Group III (2002–2011, n = 47; after publication of the Japanese guideline for RPGN). Results There were no significant differences in blood pressure, renal function or anti-neutrophil cytoplasmic antibody titer between groups. On the other hand, the rate of crescent formation and degree of interstitial inflammatory cell infiltration were decreased in Group III. Serum creatinine (\3.0, 3.0–6.0, C6.0 mg/dL) and crescent formation (\30, 30–50, 50–80, C80 %) were significant renal prognostic factors in Group III [serum creatinine: hazard ratio (HR) 4.79, 95 % confidence interval (CI) 1.43–16.1, P = 0.011; crescent formation: HR 2.86, 95 % CI 1.06–7.73, P = 0.039]. Furthermore, renal survival rate of patients with crescent formation \50 % and patient survival rate of patients with serum creatinine \3 mg/dL were improved in Group III. Conclusion Patients with CreGN were diagnosed in the early phase of crescent formation and outcome has improved in recent years.

[1]  Irmgard Neumann,et al.  Histopathologic classification of ANCA-associated glomerulonephritis. , 2010, Journal of the American Society of Nephrology : JASN.

[2]  Kenneth G. C. Smith,et al.  A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. , 2009, Arthritis and rheumatism.

[3]  Y. Tomino,et al.  A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity , 2009, Clinical and Experimental Nephrology.

[4]  L. Mouthon,et al.  Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. , 2008, The New England journal of medicine.

[5]  D. Abramowicz,et al.  Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. , 2007, Journal of the American Society of Nephrology : JASN.

[6]  Y. Hiki,et al.  Cytapheresis for the Treatment of Myeloperoxidase Antineutrophil Cytoplasmic Autoantibody‐Associated Vasculitis: A Pilot Study of 21 Patients , 2006, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[7]  R. Wolterbeek,et al.  Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. , 2006, Journal of the American Society of Nephrology : JASN.

[8]  T. Kita,et al.  Clinical Efficacy of Intravenous Immunoglobulin for Patients with MPO-ANCA-Associated Rapidly Progressive Glomerulonephritis , 2005, Nephron Clinical Practice.

[9]  M. Nagata,et al.  Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  V. Tesar,et al.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. , 2003, The New England journal of medicine.

[11]  H. V. van Houwelingen,et al.  Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. , 2002, Kidney international.

[12]  J. Hermans,et al.  Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. , 1999, Kidney international.

[13]  H. Kida,et al.  Methylprednisolone pulse therapy in two clinical types of crescentic glomerulonephritis. , 1998, Internal medicine.

[14]  H. Kida,et al.  Two distinct types of crescentic glomerulonephritis. , 1992, Clinical nephrology.

[15]  J. Heaf,et al.  Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis--a clinical randomized controlled trial. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  L. Mouthon,et al.  Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. , 2008, Arthritis and rheumatism.

[17]  A. Soleiman,et al.  Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.